| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Rakin Kevin, Director
Granted 176,000 Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Neels Guido J, Director
Granted 117,000 Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Colpman David, Director
Granted 117,000 Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Makes Brigid, Director
Granted 117,000 Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Williams Michelle LeRoux, CHIEF SCIENTIFIC OFFICER
Granted 446,000 Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Ferguson Matthew, CHIEF FINANCIAL OFFICER
Granted 446,000 Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Mills C Randal, Director
Granted 895,000 Stock Option (Right to Buy) |
| 10 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch |
| 14 Sep 2026 |
Form 4: Williams Michelle LeRoux, CHIEF SCIENTIFIC OFFICER
Received 12,500 shares by exercise or conversion · Gave up 4,269 shares to cover exercise price or tax ($3.42K) |
| 14 Sep 2026 |
Form 4: Ferguson Matthew, CHIEF FINANCIAL OFFICER
Received 12,500 shares by exercise or conversion · Gave up 4,486 shares to cover exercise price or tax ($3.59K) |
| 14 Sep 2026 |
Form 4: Mills C Randal, Director
Received 27,083 shares by exercise or conversion · Gave up 9,718 shares to cover exercise price or tax ($7.77K) |
| 21 Aug 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
On August 17, 2026, Elutia Inc. (the “Company”) completed the previously announced sale of its Women’s Health segment (the “SimpliDerm Business”) to Cellution Biologics Inc. (“Cellution Biologics” or the “Buyer”). The sale (the “SimpliDe... |
| 14 Aug 2026 | FORM S-8 |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Funded through launch: secured up to $26 million of capital without an equity offering |
| 11 Aug 2026 | SCHEDULE 13G |
| 07 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 20 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGISTRANT CUSTOMARILY AND ACTUALLY TR... |
Loading...